Present situation and advances on the nimotuzumab related radiosensitivity research / 实用肿瘤学杂志

ABSTRACT

With data support from abundant research ,epithelial growth factor receptor ( EGFR) signaling pathway is associated with radiotherapy resistance .EGFR inhibition has become one of methods to increase radio-sensitivity.As the first EGFR monoclonal antibody developed by China and Cuba ,nimotuzumab demonstrates its distinct clinical characteristics and has been extensively explored in head and neck cancer , esophageal cancer , high grade glioma .This article mainly reviews the present situation and recent advances on the radiosensitivity re -search of nimotuzumab .